Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Cipriani, Andrea ^a   Boso, Marianna ^b   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AGITATION; AKATHISIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRANULOCYTOPENIA; HUMAN; HYPERSALIVATION; PSYCHOSIS; REVIEW; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 70049104227     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006324.pub2     Document Type: Review

References (63)

1. Genç Y, Taner E, Candansayar S. Comparison of clozapine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Advances in Therapy 2007;24(1):1-13.
2. Kong QR. Sulpiride clozapine combined high and lowdoses observed in the treatment of schizophrenia. Shandong Archives of Psychiatry 2001;14:138-139
3. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology 2009;23:305-314
4. Bao XQ. A double-blind study on the effect of clozapine penfluridol and chlorpromazine in the treatment of schizophrenia. Chung Hua Shen Ching Ching Shen Ko Tsa Chih [Chinese Journal of Neurology and Psychiatry] 1988;21(5):274-276
5. Cao HJ, You HF, Fan FL, Zhang J. The control study of risperidone and clozapine for the treatment-resistant schizophrenia. Chinese Journal of Medicine Research 2003;3(4):316-319
6. Cooper D, Moisan J, Gaudet M, Abdous B, Gregoire JP. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Canadian Journal of Psychiatry 2005;50(14):901-908
7. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol+ biperiden, thioridazine, and clozapine. Psychopharmacology 1978;59(2):105-112
8. Glick ID, Zaninelli R, Hsu C, Young FK,Weiss L, Gunay I, Kumar V. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. Journal of Clinical Psychiatry 2004;65(5):679-685
9. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 1996;153(12):1628-1630
10. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R, Clozapine and Risperidone Enhancement (CARE) Study Group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine 2006;354(5):472-482
11. Josiassen R, Joseph A, Kohegyi E, PaingW. Clozapine augmentation with risperidone in refractory schizophrenia. Schizophrenia Research 2003;60:288.
12. Pickar D, Litman RE, Hong WW, Su TP, Weissman EM, Hsiao JK, Potter WZ. Clinical response to clozapine in patients with schizophrenia. Archives of General Psychiatry 1994;51(2):159-160
13. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 1999;156(1):145-147
14. Qi SX. Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders 1990;16(2):90-92
15. Shen J, Feng Z, Guo J, Wang W, Wang Z. Comparative study on therapy of schizophrenia with quetiapine and clozapine. Tianjin Pharmacy 2004;16(1):38-39
16. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P,Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry 1997;171:569-573
17. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology 2003;23(3):223-228
18. Stryjer R, Strous R, Bar F, Shaked G, Shiloh R, Rozencwaig S, Grupper D, Buchman N, Kotler M, Rabey JM, Weizman A. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Human Psychopharmacology 2004;19(5):343-346
19. Wang R, Geng Y, Pan D, Zhang S. A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrehia. Chinese Journal of Pharmaco Epiolemiology 2002;11(5):230-231
20. Welbel L. Differences in the clinical effect of various neuroleptics [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14(2):113-118
21. Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, Ertugrul A, Jayathilake K, Gogus A, Tunca Z, Meltzer HY. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry 2005;66(1):63-72.
22. Yang X, Hang YL, Jia WLQ, Wei LM. Clozapine combined with chlorpromazine in the treatment of positive symptoms in schizophrenia. Shanghai Psychological Medicine 1994;6(2):71-72
23. Zhu Y, Zhang S, Zhang D. A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. Journal of Clinical Psychological Medicine 1999;9(4):204-205
24. Zhu H, Yu G, Deng D. A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia. Journal of Clinical Psychological Medicine 2002;12(1):15-17
25. Randomised Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. Ongoing study September 2006.
26. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
27. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd Edition. American Journal of Psychiatry, 2004:1-114.
28. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
29. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophrenia Bulletin 2009;35(2):458-468 [DOI: 10.1093/schbul/sbn030]
30. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-676
31. Bland JM. Statistics notes. Trials randomised in clusters. British Medical Journal 1997;315:600.
32. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-690
33. Chakos M, Lieberman J, Hoffman E. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review andmeta-analysis of randomized trials. American Journal of Psychiatry 2001;158:518-526
34. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science 1980;7:233.
35. Conley RR, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry 2001;50:898-911.
36. Correll CU, Kissling W, Rummel C, Leucht S. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004579]
37. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vsmonotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2008;April 21:[Epub ahead of print].
38. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-629
39. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2]
40. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;13:629-634
41. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;149:876-883
42. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-883
43. Guy U. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health 1976.
44. Hamilton M. A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
45. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 2005;73:139-145
46. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd, 2008.
47. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008.
48. Kane J, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-796
49. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
50. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. European Psychiatry 2005;20(5-6):409-415
51. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-252
52. Mouaffak F, Tranulis C, Gourevitch R. Augmentation strategies of clozapine with antipsychotics in the treatment of ultra resistant schizophrenia. Clinical Neuropharmacology 2006;29:28-33.
53. Mule S, Cipriani A, Barbui C. Aripiprazole in addition to clozapine in partially responsive patients with schizophrenia. A critical review of case series. Clinical Schizophrenia& Related Psychoses 2008;1:341-347
54. National Institute for Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE Guidelines 2002.
55. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
56. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-872
57. Rosenheck R, Cramer J, XuW, et al.A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. New England Journal of Medicine 1997;337:809-815
58. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
59. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of AmericanMedical Association 1995;273:408-412
60. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. Journal Clinical Psychiatry 2004;65:1597-1600.
61. Simpson EN, Angus JWF. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-19
62. Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neurolepticmedication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD000059.pub2]
63. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo. 2007.